comparemela.com

Page 3 - Gilead Sciences Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Ts Madison And Dominique Morgan Launch The Ts Madison Starter House

Gilead Sciences, Inc (NASDAQ:GILD) Shares Acquired by Capital International Sarl

Capital International Sarl lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 19.4% in the fourth quarter, HoldingsChannel reports. The firm owned 69,414 shares of the biopharmaceutical company’s stock after buying an additional 11,255 shares during the period. Capital International Sarl’s holdings in Gilead Sciences were worth $5,623,000 at the end of […]

Tower Research Capital LLC TRC Has $16 29 Million Holdings in Gilead Sciences, Inc (NASDAQ:GILD)

Tower Research Capital LLC TRC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 208.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 201,060 shares of the biopharmaceutical company’s stock after acquiring an additional 135,782 shares during the quarter. Tower […]

Tower Research Capital LLC TRC Has $16 29 Million Holdings in Gilead Sciences, Inc (NASDAQ:GILD)

Tower Research Capital LLC TRC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 208.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 201,060 shares of the biopharmaceutical company’s stock after acquiring an additional 135,782 shares during the quarter. Tower […]

National Institutes of Health Kickstarts Gilead Sponsored Trials For Twice-Yearly HIV Prevention Injection - Gilead Sciences (NASDAQ:GILD)

The US National Institutes of Health has launched two clinical trials to test a new long-acting form of HIV PrEP in cisgender women and people who inject drugs. These mid-stage studies will evaluate the safety and pharmacokinetics of lenacapavir, a bi-annual injectable antiretroviral drug.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.